Skip to main content

Advertisement

SpringerLink
Log in

Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Gastric cancer is often diagnosed in advanced stage. Palliative chemotherapy or best supportive care is recommended for patients with metastatic gastric patients. In several clinical trials, palliative chemotherapy improved overall survival (OS) and progression-free survival (PFS), but the survival benefit of second-line chemotherapy was demonstrated in small cohort studies. The main aim of our study was to compare retrospectively the efficacy of second-line modified EOX (epirubicin, oxaliplatin and capecitabine) [mEOX] and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel–cisplatin–fluorouracil (DCF) regimen. Metastatic gastric cancer patients who progressed on modified DCF regimens were included. A total 105 patients were included to this study; 55 and 50 patients were treated with mEOX and FOLFIRI regimens, respectively. The clinicopathological and demographic characteristics of all patients were collected from the medical charts. Kaplan–Meier survival analysis was carried out for PFS and OS. The median follow-up of our study was 16 (4–85) months. In both groups, all of the patients were treated with first-line mDCF. Median cycle of second-line chemotherapy was 3 (1–8) and 3.5 (1–6) in EOX and FOLFIRI groups, respectively (P = 0.44). Overall response rate was observed in 34.6 % and 42.0 % of patients second-line chemotherapy in mEOX and FOLFIRI arms, respectively (P = 0.17). Median PFS was 5.5 and 6.3 months in mEOX and FOLFIRI arms, respectively (P = 0.98). Median OS was 6.9 and 7.0 months in mEOX and FOLFIRI arms, respectively, from the time of beginning second-line chemotherapy protocol (P = 0.89). As compared with FOLFIRI regimen, mEOX regimen was associated with less neutropenia, thrombocytopenia and anemia. Dose reduction and dose delay were significantly higher in FOLFIRI group compared to mEOX group (P < 0.001). In our trial, triplet regimens mEOX and FOLFIRI regimens have similar efficacy as second-line treatment for patients with metastatic gastric cancer. FOLFIRI regimen was associated with more hematological toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  2. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–14.

    Article  PubMed  CAS  Google Scholar 

  3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72(1):37–41.

    Article  PubMed  CAS  Google Scholar 

  4. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.

    Article  PubMed  Google Scholar 

  5. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.

    Article  PubMed  CAS  Google Scholar 

  6. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163–8.

    Article  PubMed  CAS  Google Scholar 

  7. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(3):587–91.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.

    Article  PubMed  CAS  Google Scholar 

  9. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–7.

    Article  PubMed  CAS  Google Scholar 

  10. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.

    Article  PubMed  CAS  Google Scholar 

  11. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.

    Article  PubMed  CAS  Google Scholar 

  12. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882–7.

    Article  PubMed  Google Scholar 

  13. Meng C, Yin H, Sun Z, Zhou J, Chen S, Bai C, et al. Adjuvant chemotherapy with docetaxel, cisplatin, and continuous-infusion 5-fluorouracil for gastric cancer: a phase II study. Transl Oncol. 2014;7(2):277–83.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chi Y, Ren JH, Yang L, Cui CX, Li JL, Wang JW. Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma. Chin Med J (Engl). 2011;124(19):2997–3002.

    CAS  Google Scholar 

  15. Ozdemir NY, Abali H, Oksuzoglu B, Budakoglu B, Uncu D, Guler T, et al. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol. 2010;27(3):680–4.

    Article  PubMed  CAS  Google Scholar 

  16. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.

    Article  PubMed  CAS  Google Scholar 

  17. Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014;50(8):1437–45.

    Article  PubMed  CAS  Google Scholar 

  18. Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24(11):2850–4.

    Article  PubMed  CAS  Google Scholar 

  19. Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, et al. Gastric cancer, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11(5):531–46.

    CAS  Google Scholar 

  20. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):57–63.

    Article  Google Scholar 

  21. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 1994;21(7):1033–8.

    PubMed  CAS  Google Scholar 

  22. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 2004;34(1):8–13.

    Article  PubMed  Google Scholar 

  23. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002;16(5 Suppl 5):16–8.

    Google Scholar 

  24. Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, et al. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs. 2005;16(6):621–5.

    Article  PubMed  CAS  Google Scholar 

  25. Rino Y, Yukawa N, Sato T, Oshima T, Tanabe H, Yamamoto Y, et al. Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer. Mol Clin Oncol. 2013;1(4):749–52.

    PubMed  CAS  PubMed Central  Google Scholar 

  26. Kaya AO, Coskun U, Gumus M, Dane F, Ozkan M, Isikdogan A, et al. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. J Chemother. 2012;24(4):217–20.

    Article  PubMed  CAS  Google Scholar 

  27. Maugeri-Sacca M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso S, et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res. 2013;32(1):67.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Miyamoto K, Yoshida S, Saito D, Shimada Y, Tajiri H, Yamaguchi H, et al. Pilot phase II study of cis-diamminedichloroplatinum (II) against metastatic gastric cancers. Jpn J Clin Oncol. 1990;20(2):169–76.

    PubMed  CAS  Google Scholar 

  29. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol. 2004;27(5):477–80.

    Article  PubMed  CAS  Google Scholar 

  30. Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010;136(4):503–10.

    Article  PubMed  CAS  Google Scholar 

  31. Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Yong D, et al. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19(10):1013–8.

    Article  PubMed  CAS  Google Scholar 

  32. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30(3 Suppl 7):3–14.

    Article  CAS  Google Scholar 

  33. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors indicated no potential conflict of interests.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, 06800, Ankara, Turkey

    Mehmet Ali Nahit Sendur, Nuriye Ozdemir & Doğan Yazılıtaş

  2. Department of Medical Oncology, Ankara Oncology Education and Research Hospital, Ankara, Turkey

    Tahsin Özatlı, Ahmet Şiyar Ekinci, Berna Oksuzoglu & Nurullah Zengin

  3. Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey

    Ozan Yazıcı

  4. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Sercan Aksoy

  5. Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey

    Yusuf Günaydın & Mustafa Benekli

Authors
  1. Mehmet Ali Nahit Sendur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nuriye Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tahsin Özatlı
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozan Yazıcı
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sercan Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmet Şiyar Ekinci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Doğan Yazılıtaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yusuf Günaydın
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Berna Oksuzoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mustafa Benekli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nurullah Zengin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Ali Nahit Sendur.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sendur, M.A.N., Ozdemir, N., Özatlı, T. et al. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Med Oncol 31, 153 (2014). https://doi.org/10.1007/s12032-014-0153-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0153-y

Keywords

Search

Navigation